Published in J Psychopharmacol on June 21, 2011
Hedgehog agonist therapy corrects structural and cognitive deficits in a Down syndrome mouse model. Sci Transl Med (2013) 1.70
Trisomy 21 and early brain development. Trends Neurosci (2011) 1.28
GABAA receptor subtypes: Therapeutic potential in Down syndrome, affective disorders, schizophrenia, and autism. Annu Rev Pharmacol Toxicol (2013) 1.20
Identification of the translocation breakpoints in the Ts65Dn and Ts1Cje mouse lines: relevance for modeling Down syndrome. Mamm Genome (2011) 1.19
Deficits in cognition and synaptic plasticity in a mouse model of Down syndrome ameliorated by GABAB receptor antagonists. J Neurosci (2012) 1.17
Down syndrome: the brain in trisomic mode. Nat Rev Neurosci (2012) 1.10
Functional regulation of GABAA receptors in nervous system pathologies. Curr Opin Neurobiol (2011) 1.03
Modulation of GABAergic transmission in development and neurodevelopmental disorders: investigating physiology and pathology to gain therapeutic perspectives. Front Cell Neurosci (2014) 1.01
Mouse models of Down syndrome as a tool to unravel the causes of mental disabilities. Neural Plast (2012) 1.00
Neurological phenotypes for Down syndrome across the life span. Prog Brain Res (2012) 0.98
Tonic inhibition in dentate gyrus impairs long-term potentiation and memory in an Alzheimer's [corrected] disease model. Nat Commun (2014) 0.98
GluN2B antagonism affects interneurons and leads to immediate and persistent changes in synaptic plasticity, oscillations, and behavior. Neuropsychopharmacology (2013) 0.93
Pharmacological approaches to improving cognitive function in Down syndrome: current status and considerations. Drug Des Devel Ther (2014) 0.93
Short-term treatment with the GABAA receptor antagonist pentylenetetrazole produces a sustained pro-cognitive benefit in a mouse model of Down's syndrome. Br J Pharmacol (2013) 0.88
Overexpression of Dyrk1A is implicated in several cognitive, electrophysiological and neuromorphological alterations found in a mouse model of Down syndrome. PLoS One (2014) 0.87
A Sonic hedgehog (Shh) response deficit in trisomic cells may be a common denominator for multiple features of Down syndrome. Prog Brain Res (2012) 0.87
Dentate gyrus mediates cognitive function in the Ts65Dn/DnJ mouse model of Down syndrome. Hippocampus (2013) 0.86
The App-Runx1 region is critical for birth defects and electrocardiographic dysfunctions observed in a Down syndrome mouse model. PLoS Genet (2012) 0.85
Chronic Treatment with a Promnesiant GABA-A α5-Selective Inverse Agonist Increases Immediate Early Genes Expression during Memory Processing in Mice and Rectifies Their Expression Levels in a Down Syndrome Mouse Model. Adv Pharmacol Sci (2011) 0.85
Adult-onset fluoxetine treatment does not improve behavioral impairments and may have adverse effects on the Ts65Dn mouse model of Down syndrome. Neural Plast (2012) 0.83
Human chromosome 21 orthologous region on mouse chromosome 17 is a major determinant of Down syndrome-related developmental cognitive deficits. Hum Mol Genet (2013) 0.83
From abnormal hippocampal synaptic plasticity in down syndrome mouse models to cognitive disability in down syndrome. Neural Plast (2012) 0.82
Monoacylglycerol lipase inhibitor JZL184 improves behavior and neural properties in Ts65Dn mice, a model of down syndrome. PLoS One (2014) 0.81
Pathophysiological power of improper tonic GABA(A) conductances in mature and immature models. Front Neural Circuits (2013) 0.81
Pharmacological correction of excitation/inhibition imbalance in Down syndrome mouse models. Front Behav Neurosci (2015) 0.80
Building an adaptive brain across development: targets for neurorehabilitation must begin in infancy. Front Behav Neurosci (2015) 0.79
GABA receptor subunit distribution and FMRP-mGluR5 signaling abnormalities in the cerebellum of subjects with schizophrenia, mood disorders, and autism. Schizophr Res (2014) 0.79
Adaptive and pathological inhibition of neuroplasticity associated with circadian rhythms and sleep. Behav Neurosci (2014) 0.79
Protein dynamics associated with failed and rescued learning in the Ts65Dn mouse model of Down syndrome. PLoS One (2015) 0.78
GABAergic dysfunction in pediatric neuro-developmental disorders. Front Cell Neurosci (2013) 0.78
Context-Dependent Modulation of GABAAR-Mediated Tonic Currents. J Neurosci (2016) 0.78
Molecular and cellular alterations in Down syndrome: toward the identification of targets for therapeutics. Neural Plast (2012) 0.78
Down Syndrome Cognitive Phenotypes Modeled in Mice Trisomic for All HSA 21 Homologues. PLoS One (2015) 0.77
Altered Intrinsic Pyramidal Neuron Properties and Pathway-Specific Synaptic Dysfunction Underlie Aberrant Hippocampal Network Function in a Mouse Model of Tauopathy. J Neurosci (2016) 0.77
Disinhibition, an emerging pharmacology of learning and memory. F1000Res (2017) 0.75
Evidence that increased Kcnj6 gene dose is necessary for deficits in behavior and dentate gyrus synaptic plasticity in the Ts65Dn mouse model of Down syndrome. Neurobiol Dis (2017) 0.75
The GABAergic Hypothesis for Cognitive Disabilities in Down Syndrome. Front Cell Neurosci (2017) 0.75
Tc1 mouse model of trisomy-21 dissociates properties of short- and long-term recognition memory. Neurobiol Learn Mem (2016) 0.75
Weaker control of the electrical properties of cerebellar granule cells by tonically active GABAA receptors in the Ts65Dn mouse model of Down's syndrome. Mol Brain (2013) 0.75
Selective Pharmacological Augmentation of Hippocampal Activity Produces a Sustained Antidepressant-Like Response without Abuse-Related or Psychotomimetic Effects. Int J Neuropsychopharmacol (2017) 0.75
Differential Alteration in Expression of Striatal GABAAR Subunits in Mouse Models of Huntington's Disease. Front Mol Neurosci (2017) 0.75
GABA(A) receptors: immunocytochemical distribution of 13 subunits in the adult rat brain. Neuroscience (2000) 5.81
The distribution of 13 GABAA receptor subunit mRNAs in the rat brain. I. Telencephalon, diencephalon, mesencephalon. J Neurosci (1992) 5.02
A mouse model for Down syndrome exhibits learning and behaviour deficits. Nat Genet (1995) 4.95
Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome. Nat Neurosci (2007) 3.74
Enhanced learning and memory and altered GABAergic synaptic transmission in mice lacking the alpha 5 subunit of the GABAA receptor. J Neurosci (2002) 2.87
Hippocampal long-term potentiation suppressed by increased inhibition in the Ts65Dn mouse, a genetic model of Down syndrome. J Neurosci (2004) 2.73
GABA(A) receptor subunits in the rat hippocampus I: immunocytochemical distribution of 13 subunits. Neuroscience (1997) 2.27
Down syndrome--recent progress and future prospects. Hum Mol Genet (2009) 1.85
A behavioral assessment of Ts65Dn mice: a putative Down syndrome model. Neurosci Lett (1995) 1.70
Epidemiology of Down syndrome. Ment Retard Dev Disabil Res Rev (2007) 1.67
Altered long-term potentiation in the young and old Ts65Dn mouse, a model for Down Syndrome. Neuropharmacology (1998) 1.63
L-655,708 enhances cognition in rats but is not proconvulsant at a dose selective for alpha5-containing GABAA receptors. Neuropharmacology (2006) 1.46
Chronic pentylenetetrazole but not donepezil treatment rescues spatial cognition in Ts65Dn mice, a model for Down syndrome. Neurosci Lett (2008) 1.38
Down syndrome, Alzheimer's disease and seizures. Brain Dev (2005) 1.29
An inverse agonist selective for alpha5 subunit-containing GABAA receptors enhances cognition. J Pharmacol Exp Ther (2005) 1.28
Ts65Dn, a mouse model of Down syndrome, exhibits increased GABAB-induced potassium current. J Neurophysiol (2006) 1.23
Autoradiographic localization of alpha5 subunit-containing GABAA receptors in rat brain. Brain Res (1999) 1.23
RO4938581, a novel cognitive enhancer acting at GABAA alpha5 subunit-containing receptors. Psychopharmacology (Berl) (2008) 1.17
Preclinical and clinical pharmacology of the GABAA receptor alpha5 subtype-selective inverse agonist alpha5IA. Pharmacol Ther (2009) 1.13
The prevalance of epilepsy among mongols related to age. J Ment Defic Res (1974) 1.13
Behavioral validation of the Ts65Dn mouse model for Down syndrome of a genetic background free of the retinal degeneration mutation Pde6b(rd1). Behav Brain Res (2009) 1.13
Spatial memory deficits in segmental trisomic Ts65Dn mice. Behav Brain Res (1996) 1.12
A year of unprecedented progress in Down syndrome basic research. Ment Retard Dev Disabil Res Rev (2007) 1.05
Blockade of alcohol's amnestic activity in humans by an alpha5 subtype benzodiazepine receptor inverse agonist. Neuropharmacology (2007) 1.05
An inverse agonist selective for alpha5 subunit-containing GABAA receptors improves encoding and recall but not consolidation in the Morris water maze. Psychopharmacology (Berl) (2006) 1.04
Impaired neurogenesis, neuronal loss, and brain functional deficits in the APPxPS1-Ki mouse model of Alzheimer's disease. Neurobiol Aging (2009) 1.03
Selective, orally active gamma-aminobutyric acidA alpha5 receptor inverse agonists as cognition enhancers. J Med Chem (2004) 1.02
"Sighted C3H" mice--a tool for analysing the influence of vision on mouse behaviour? Front Biosci (2008) 1.01
Seizure disorders in Down syndrome. Arch Neurol (1991) 0.96
Impaired conditioned taste aversion learning in APP transgenic mice. Neurobiol Aging (2004) 0.93
GABA(A) receptor subtype-selective efficacy: TPA023, an alpha2/alpha3 selective non-sedating anxiolytic and alpha5IA, an alpha5 selective cognition enhancer. CNS Neurosci Ther (2008) 0.87
Collaborative learning: comparison of outcomes for typically developing children and children with intellectual disabilities. Am J Ment Retard (2007) 0.79
Characterization of the solubility of a poorly soluble hydroxylated metabolite in human urine and its implications for potential renal toxicity. Pharmazie (2005) 0.78
Classification of human chromosome 21 gene-expression variations in Down syndrome: impact on disease phenotypes. Am J Hum Genet (2007) 2.06
Oxygen free radical involvement in ischemia and reperfusion injury to brain. Neurosci Lett (1988) 1.38
Integrating whole transcriptome assays on a lab-on-a-chip for single cell gene profiling. Lab Chip (2008) 1.38
Benzodiazepine impairs and beta-carboline enhances performance in learning and memory tasks. Nature (1986) 1.33
The cerebellar transcriptome during postnatal development of the Ts1Cje mouse, a segmental trisomy model for Down syndrome. Hum Mol Genet (2004) 1.29
The human visual system averages speed information. Vision Res (1992) 1.28
Parvalbumin deficiency affects network properties resulting in increased susceptibility to epileptic seizures. Mol Cell Neurosci (2004) 1.25
Cloning of a balanced translocation breakpoint in the DiGeorge syndrome critical region and isolation of a novel potential adhesion receptor gene in its vicinity. Hum Mol Genet (1995) 1.20
HtrA1-dependent proteolysis of TGF-beta controls both neuronal maturation and developmental survival. Cell Death Differ (2008) 1.13
Transcriptional disruptions in Down syndrome: a case study in the Ts1Cje mouse cerebellum during post-natal development. J Neurochem (2006) 1.04
Impaired neurogenesis, neuronal loss, and brain functional deficits in the APPxPS1-Ki mouse model of Alzheimer's disease. Neurobiol Aging (2009) 1.03
Copper-catalyzed nitrogen transfer mediated by iodosylbenzene PhI=O. J Am Chem Soc (2001) 1.01
The role of the rat prelimbic/infralimbic cortex in working memory: not involved in the short-term maintenance but in monitoring and processing functions. Neuroscience (2006) 1.01
Anxiogenic effects of methyl-beta-carboline-3-carboxylate in a light/dark choice situation. Pharmacol Biochem Behav (1987) 1.00
The expression and function of Ca(2+)-sensing receptors in rat mesenteric artery; comparative studies using a model of type II diabetes. Br J Pharmacol (2008) 0.98
Characterization of a new brain-specific isoform of the EWS oncoprotein. Eur J Biochem (2001) 0.97
Cre/loxP-mediated chromosome engineering of the mouse genome. Handb Exp Pharmacol (2007) 0.89
[Alzheimer's disease: lesions and their progression]. Rev Neurol (Paris) (1999) 0.88
Synthesis of cyclic sulfonamides via intramolecular copper-catalyzed reaction of unsaturated iminoiodinanes. Org Lett (2000) 0.87
One-year longitudinal evaluation of sensorimotor functions in APP751SL transgenic mice. Genes Brain Behav (2008) 0.87
Selection of oligonucleotides for whole-genome microarrays with semi-automatic update. Bioinformatics (2008) 0.86
In vivo bidirectional modulatory effect of benzodiazepine receptor ligands on GABAergic transmission evaluated by positron emission tomography in non-human primates. Brain Res (1991) 0.86
Chronic Treatment with a Promnesiant GABA-A α5-Selective Inverse Agonist Increases Immediate Early Genes Expression during Memory Processing in Mice and Rectifies Their Expression Levels in a Down Syndrome Mouse Model. Adv Pharmacol Sci (2011) 0.85
Altered emotional and motivational processing in the transgenic rat model for Huntington's disease. Neurobiol Learn Mem (2010) 0.85
VARAN: a web server for variability analysis of DNA microarray experiments. Bioinformatics (2004) 0.84
A novel positive allosteric modulator of the GABA(A) receptor: the action of (+)-ROD188. Br J Pharmacol (2000) 0.84
Sustained calcium signalling and caspase-3 activation involve NMDA receptors in thymocytes in contact with dendritic cells. Cell Death Differ (2010) 0.83
Transmembrane protein 50b (C21orf4), a candidate for Down syndrome neurophenotypes, encodes an intracellular membrane protein expressed in the rodent brain. Neuroscience (2008) 0.82
Benzodiazepine receptor inverse agonist-induced kindling of rats alters learning and glutamate binding. Pharmacol Biochem Behav (2000) 0.82
Fiber Tracts Anomalies in APPxPS1 Transgenic Mice Modeling Alzheimer's Disease. J Aging Res (2011) 0.80
Cognitive enhancing properties of beta-CCM infused into the nucleus basalis magnocellularis of the rat. Brain Res (1992) 0.80
Benzodiazepine receptors studied in living primates by positron emission tomography: antagonist interactions. Eur J Pharmacol (1988) 0.79
Enhancement of performance by methyl beta-carboline-3-carboxylate, in learning and memory tasks. Brain Res Bull (1987) 0.79
N1-Arylsulfonyl-N2-(1-aryl)ethyl-3-phenylpropane-1,2-diamines as novel calcimimetics acting on the calcium sensing receptor. Bioorg Med Chem Lett (2000) 0.78
Quantification of interstitial fibrosis by image analysis on routine renal biopsy 1 year after transplantation in patients managed by C2 monitoring of cyclosporine microemulsion. Transplant Proc (2007) 0.78
Loreclezole as a simple functional marker for homomeric rho type GABA(C) receptors. Eur J Pharmacol (2000) 0.78
In vivo binding of (3H)Ro 15-1788 in mice: comparison with the in vivo binding of (3H)flunitrazepam. Life Sci (1988) 0.78
Relationships between benzodiazepine receptors, impairment of GABAergic transmission and convulsant activity of beta-CCM: a PET study in the baboon Papio papio. Epilepsy Res (1991) 0.78
In vivo binding of beta-carbolines in mice: regional differences and correlation of occupancy to pharmacological effects. Mol Pharmacol (1988) 0.78
Effects of divalent cations and of a calcimimetic on adrenocorticotropic hormone release in pituitary tumor cells. Biochem Biophys Res Commun (1997) 0.78
Cytotoxic activities of novel hexahydroindolizino[8,7-b]indole derivatives prepared by 1,3-dipolar cycloaddition reactions of 3,4-dihydro-beta-carboline ylides. Bioorg Med Chem (2001) 0.77
Opposite effects of cholinergic agents and benzodiazepine receptor ligands in a passive avoidance task in rats. Neurosci Lett (1994) 0.77
Differential cross talk of ROD compounds with the benzodiazepine binding site. Mol Pharmacol (2001) 0.77
Anticonvulsant activity of the diaryltriazine, LY81067: studies using electroencephalographic recording and positron emission tomography. Neuropharmacology (1989) 0.77
Characterization of convulsions induced by methyl beta-carboline-3-carboxylate in mice. Eur J Pharmacol (1984) 0.76
Synthesis and GABA(A) receptor activity of 6-oxa-analogs of neurosteroids. Steroids (2000) 0.76
[Morphologic and molecular neuropathology of Alzheimer's disease]. Ann Pharm Fr (2009) 0.76
Use of bicuculline, a GABA antagonist, as a template for the development of a new class of ligands showing positive allosteric modulation of the GABA(A) receptor. Bioorg Med Chem Lett (2000) 0.76
Transcription profile analysis reveals that OBP-1F mRNA is downregulated in the olfactory mucosa following food deprivation. Chem Senses (2007) 0.75
Molecular structure of 3-(methoxycarbonyl) amino-beta-carboline, a selective antagonist of the sedative effects of diazepam. Mol Pharmacol (1987) 0.75
beta-Carboline-induced seizures in mice: genetic analysis. Pharmacol Biochem Behav (1989) 0.75
3-(Methoxycarbonyl)-amino-beta-carboline, a selective antagonist of the sedative effects of benzodiazepines. Eur J Pharmacol (1986) 0.75
Changes in benzodiazepine binding in a subkindling situation. Epilepsia (2000) 0.75
3-Amino-beta-carboline derivatives and the benzodiazepine receptor. Synthesis of a selective antagonist of the sedative action of diazepam. J Med Chem (1985) 0.75
Synthetic routes to 4-amino-3-carboxy-beta-carboline derivatives: incidental formation of novel furo[3,4-c]-beta-carbolin-2-ones displaying high affinities for the benzodiazepine receptor. J Med Chem (1995) 0.75
The benzodiazepine receptor ligand, methyl beta-carboline-3-carboxylate, is both sedative and proconvulsant in chicks. Life Sci (1986) 0.75
Methyl-beta-carboline-induced convulsions are antagonized by Ro 15-1788 and by propyl-beta-carboline. Eur J Pharmacol (1982) 0.75
Genetic control of murine limb morphogenesis: relationships with human syndromes and evolutionary relevance. Mol Cell Endocrinol (1998) 0.75
Olfactory memory in rats, cholinergic agents and benzodiazepine receptor ligands. J Physiol Paris (1999) 0.75
Synthesis and benzodiazepine receptor (omega receptor) affinities of 3-substituted derivatives of pyrrolo[2,3-c]pyridine-5-carboxylate, a novel class of omega1 selective ligands. Bioorg Med Chem (1999) 0.75
Distinct behavioral and pharmacological effects of two benzodiazepine antagonists: Ro 15-1788 and methyl beta-carboline. Adv Biochem Psychopharmacol (1983) 0.75
An automatic image analysis approach to quantify stained cell cultures. Cell Mol Biol (Noisy-le-grand) (2007) 0.75
EDPC: a novel high affinity ligand for the benzodiazepine site on rat GABA(A) receptors. Neurosci Lett (1999) 0.75
[Study of substances reacting with the benzodiazepines receptor: example of collaboration between chemists and pharmacologists]. Bull Acad Natl Med (1984) 0.75
First use of a beta-carboline as photoaffinity label for the benzodiazepine receptor. Eur J Pharmacol (1989) 0.75
Benzodiazepine receptors studied in living primates by positron emission tomography: inverse agonist interactions. Eur J Pharmacol (1987) 0.75
[3H]propyl-6-azido-beta-carboline-3-carboxylate: a new photoaffinity label for the GABAA-benzodiazepine receptor. Eur J Pharmacol (1995) 0.75
5-[1'-(2'-N-Arylsulfonyl-1',2',3',4'-tetrahydroisoquinolyl)]-4, 5-dihydro-2(3H)-furanones: positive allosteric modulators of the GABA(A) receptor with a new mode of action. J Med Chem (2000) 0.75
Hypnotic action of ethyl beta-carboline-3-carboxylate, a benzodiazepine receptor antagonist, in cats. Electroencephalogr Clin Neurophysiol (1984) 0.75
First enantiospecific synthesis of a 3,4-dihydroxy-L-glutamic acid [(3S,4S)-DHGA], a new mGluR1 agonist. Bioorg Med Chem Lett (2000) 0.75
In vivo interactions of pentylenetetrazole with benzodiazepine receptors: lack of direct correlation between benzodiazepine receptor occupancy and convulsant potency of this drug. Epilepsy Res Suppl (1992) 0.75
Methyl beta-carboline-3-carboxylate enhances performance in a multiple-trial learning task in mice. Pharmacol Biochem Behav (1990) 0.75
An Address Delivered at the Opening of the Section of Public Medicine. Br Med J (1877) 0.75